Pharvaris N.V. specializes in the research and development of targeted therapies for rare genetic and acquired conditions, primarily hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The company's pipeline is centered around deucrictibant, a small-molecule bradykinin B2 receptor antagonist. Pharvaris is developing two distinct formulations of this drug: an immediate-release capsule for the on-demand treatment of acute HAE attacks, and an extended-release tablet for prophylactic use to prevent attacks. Operating globally with key sites in the Netherlands, Switzerland, and the U.S., the company conducts multiple Phase 3 clinical trials, including the RAPIDe-3 and CHAPTER-3 studies. As a clinical-stage entity, Pharvaris does not yet generate commercial product revenue and relies on capital markets to fund its research and development activities. Its competitive position is defined by its effort to replace traditional injectable HAE therapies with more convenient, fully oral alternatives.
